TORONTO (Reuters) - QLT Inc said on Monday that it would proceed with plans to divest its topical acne treatment Aczone after the U.S. Food and Drug Administration removed key blood monitoring requirements for the treatment.
TORONTO (Reuters) - QLT Inc said on Monday that it would proceed with plans to divest its topical acne treatment Aczone after the U.S. Food and Drug Administration removed key blood monitoring requirements for the treatment.